Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study

Y. Lévy, I. Sereti, G. Tambussi, J. P. Routy, J. D. Lelièvre, J. F. Delfraissy, J. M. Molina, M. Fischl, C. Goujard, B. Rodriguez, C. Rouzioux, V. Avettand-Fenoël, T. Croughs, S. Beq, M. Morre, J. F. Poulin, R. P. Sekaly, R. Thiebaut, M. M. Lederman

Research output: Contribution to journalArticlepeer-review

Abstract

Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels

Original languageEnglish
Pages (from-to)291-300
Number of pages10
JournalClinical Infectious Diseases
Volume55
Issue number2
DOIs
Publication statusPublished - Jul 15 2012

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: Results of a phase I/IIa randomized, placebo-controlled, multicenter study'. Together they form a unique fingerprint.

Cite this